Genomic Expression, Inc.

Genomic Expression, Inc. specializes in personalized cancer treatment through its innovative OneRNA® platform, which repurposes existing drugs and develops novel RNA therapeutics for individual patients. Genomic Expression, Inc. focuses on advancing cancer care by utilizing RNA sequencing technology to provide personalized treatment options.

The company was co-founded by Gitte Pedersen and Morten Pedersen, with Gitte serving as the CEO. The firm is headquartered in New York, US. The latest funding round occurred in May 2015, with an investment from Women’s Impact Fund. Genomic Expression's primary offering is the OneRNA® platform, designed to repurpose approved drugs for individual cancer patients and develop novel RNA therapeutics.

The platform analyzes over 20,000 mRNA samples from tumor tissues, identifying tailored treatment options and clinical studies for each patient’s specific cancer profile. This approach is validated for breast and ovarian cancers and is targeted at oncologists and patients in North America and Europe. The revenue model of Genomic Expression is centered on the OneRNA® platform, supported through partnerships with healthcare providers and pharmaceutical companies, in addition to direct patient engagement. The firm has a fundraising goal of USD 1.

00 mn linked to its Series A round aimed at launching its services in women's cancers, generating revenue through service fees associated with the OneRNA® test, structured as per-test pricing for oncologists or institutions utilizing the platform for diagnostics. Genomic Expression plans to launch new products centered around the OneRNA® platform in the coming years, further enhancing its offerings in personalized cancer treatment. The company aims to expand its market presence in Europe and North America by 2025. The recent financing from Women’s Impact Fund in May 2015 will be utilized to support these growth initiatives and enhance product development.